JPRN-jRCT2041260085 Efimosfermin alfa Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines JPRN-jRCT2041260085 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 21 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2041260085 is a hot trial to watch
Metabolic Dysfunction Associated Steatohepatitis is being segmented by mechanism, treatment setting, geography and endpoint architecture. JPRN-jRCT2041260085 is notable because it evaluates Efimosfermin alfa in a Phase 3 design sponsored by GlaxoSmithKline KK. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2041260085 |
| Official title | A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2) |
| Phase / status | Phase 3 / 募集前 |
| Intervention | Efimosfermin alfa |
| Sponsor | GlaxoSmithKline KK |
| Geography | Taiwan Province, Bulgaria, Italy, Greece, Austria, South Korea, Germany, Saudi Arabia, Puerto Rico, Brazil, Argentina, Chile, Canada, Hong Kong, Japan, France, New Zealand, India, Netherlands, Belgium, Spain, Mexico, United Kingdom, United States, Singapore, Turkey, Poland, China, Australia, Israel |
| Enrollment | 21 |
| Primary endpoint | Part A: Proportion of participants achieving improvement in liver fibrosis by >= 1 stage and no worsening of MASH |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | 2032-12-10 |
Protocol design and endpoint interpretation
The indexed record describes a Phase 3 study of Efimosfermin alfa in Metabolic Dysfunction Associated Steatohepatitis.
Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 21 participants across Taiwan Province, Bulgaria, Italy, Greece, Austria, South Korea, Germany, Saudi Arabia, Puerto Rico, Brazil, Argentina, Chile, Canada, Hong Kong, Japan, France, New Zealand, India, Netherlands, Belgium, Spain, Mexico, United Kingdom, United States, Singapore, Turkey, Poland, China, Australia, Israel shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Part A: Proportion of participants achieving improvement in liver fibrosis by >= 1 stage and no worsening of MASH (time frame not reported)
- パートA: Week 96の時点で、肝線維化が1段階以上改善し、MASHの増悪が認められなかった被験者の割合 (time frame not reported)
Readout outlook and evidence gap
The current protocol points to 2032-12-10 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Trial-sourced asset: Efimosfermin alfa. The Drug & Asset MCP enrichment step is designed to add normalized targets, modality and global development status when an exact asset match is available.
Trial-sourced sponsor: GlaxoSmithKline KK. Company & Deal Intelligence MCP is the companion workflow for resolving organization identity, corporate profile and partnering context.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
JPRN-jRCT2041260085 provides a focused lens on Metabolic Dysfunction Associated Steatohepatitis development. Its value will be determined by whether Efimosfermin alfa can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
